Peptide library / Sexual & reproductive / Bremelanotide
Bremelanotide
A melanocortin receptor agonist injected before sex, approved for low desire in premenopausal women.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Hypoactive sexual desire disorder in premenopausal womenFDA approved
- Erectile dysfunction, studiedSmall human studies
How it is thought to work
Bremelanotide activates melanocortin receptors in the brain's desire pathways, unlike drugs that act on blood flow.
What the evidence shows
The RECONNECT trials showed small but statistically significant improvements in desire and distress compared with placebo.
Safety and unknowns
Nausea is very common, and a transient rise in blood pressure occurs. Skin darkening can happen with repeated use.
Regulatory status
FDA-approved as Vyleesi in 2019.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Sexual & reproductive
Buserelin
FDA-approvedA GnRH agonist used in fertility treatment and cancers in many countries.
Carbetocin
FDA-approvedA long-acting oxytocin analog used to prevent bleeding after childbirth outside the United States.
Aviptadil
FDA-approvedA synthetic version of vasoactive intestinal peptide, used by injection with phentolamine for erectile dysfunction in some countries.
General information, not medical advice. Do not buy or inject unregulated peptides.